对甲苯磺酸舒他西林 | 83105-70-8

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 中文名称: 对甲苯磺酸舒他西林
• 中文别名: 甲苯磺酸舒他西林；(2S,5R)-3,3-二甲基-4,4-二氧化-7-氧代-4-硫杂-1-氮杂双环[3.2.0]正庚烷-2-羰基氧甲基(2S,5R,6R)-6-[[(2R)-氨基苯基乙酰胺基]-3,3-二甲基-7-氧代-4-硫杂-1-氮杂双环[3.2.0]正庚烷-2-羧酸酯对甲苯磺酸盐；(2S,5R)-3,3-二甲基-4,4-二氧化-7-氧代-4-硫杂-1-氮杂双环[3.2.0]正庚烷-2-羰基氧甲基(
• 英文名称: Sultamicillin tosilate
• 英文别名: [(2S,5R)-3,3-dimethyl-4,4,7-trioxo-4λ6-thia-1-azabicyclo[3.2.0]heptane-2-carbonyl]oxymethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;hydron;4-methylbenzenesulfonate
• CAS: 83105-70-8
• 化学式: C32H38N4O12S3
• 分子量: 766.9
• InChiKey: FFCSPKNZHGIDQM-CGAOXQFVSA-N

物化性质

• 熔点：
  >140°C (dec.)
• 溶解度：
  几乎不溶于水，微溶于乙醇 (96%)。

计算性质

• 辛醇/水分配系数(LogP)：
  0.65
• 重原子数：
  51
• 可旋转键数：
  10
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  279
• 氢给体数：
  3
• 氢受体数：
  14

安全信息

• 危险品运输编号：
  5kgs
• 海关编码：
  2941101900

制备方法与用途

生物活性

Sultamicillin (tosylate) 是一种有效的口服活性 β-内酰胺酶抑制剂，具有抗菌作用。它实际上是舒巴坦与氨苄西林的双酯化合物的甲苯磺酸盐。

用途

Sultamicillin (tosylate) 主要用于抗感染治疗，适用于慢性支气管炎急性化脓性病变及其他肺部疾病、儿童患者的流感杆菌感染以及急性扁桃体炎等病症。它属于抗生素类药物。

文献信息

• GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY
  申请人：Cai Jianfeng

  公开号：US20150274782A1

  公开（公告）日：2015-10-01

  The present invention is directed to a novel class of antimicrobial agents called γ-AApeptides. The current invention provides various categories of γ-AApeptides, for example, linear γ-AApeptides, cyclic γ-AApeptides, and lipidated γ-AApeptides. γ-AApeptides of the current invention are designed to exert antimicrobial activity while being stable and non-toxic. γ-AApeptides also do not appear to lead to the development of microbial resistance in treated microorganisms. Thus, the disclosed γ-AApeptides can be used for the treatment of various medical conditions associated with pathogenic microorganisms.

  本发明涉及一种新型类别的抗微生物药物，称为γ-AA肽。当前发明提供了各种类别的γ-AA肽，例如线性γ-AA肽、环状γ-AA肽和脂质化γ-AA肽。本发明的γ-AA肽被设计为具有抗微生物活性，同时稳定且无毒。γ-AA肽似乎也不会导致被治疗微生物体内微生物产生抗药性。因此，所披露的γ-AA肽可用于治疗与病原微生物相关的各种医疗状况。
• External preparation for skin diseases containing nitroimidazole
  申请人：——

  公开号：US20030092754A1

  公开（公告）日：2003-05-15

  An external preparation for skin disease which comprises a nitroimidazole derivative represented by the following formula (I): 1 wherein R 1 , R 3 and R 4 may be the same or different and represent a hydrogen atom, a nitro group, a lower alkyl group, a substituted lower alkyl group, a lower alkenyl group, or a substituted lower alkenyl group; and R 2 represents a hydrogen atom, a lower alkyl group, a substituted lower alkyl group and a lower alkenyl group or a substituted lower alkenyl group, provided that any one of R 1 , R 3 and R 4 is a nitro group.

  一种外用制剂，用于皮肤疾病，包括以下式(I)所代表的硝基咪唑衍生物：1其中R1、R3和R4可以相同也可以不同，并表示氢原子、硝基、低烷基、取代的低烷基、低烯基或取代的低烯基；R2表示氢原子、低烷基、取代的低烷基和低烯基或取代的低烯基，只要R1、R3和R4中的任何一个是硝基。
• MANUFACTURING METHOD AND APPARATUS OF ULTRAFINE PARTICLES HAVING UNIFORM PARTICLE SIZE DISTRIBUTION
  申请人：Hwang Sung Joo

  公开号：US20110200678A1

  公开（公告）日：2011-08-18

  The present invention relates to a novel technology for forming fine particles with a size of 0.02˜3 microns from a solid that can be dissolved in a liquid solvent and is not decomposed by heat. The particle preparation technology according to the present invention may be applicable to the fields of food, cosmetics, biopolymer, polymer compositions, and pharmaceuticals.

  本发明涉及一种新型技术，用于从可溶于液体溶剂且不会被热分解的固体中形成粒径为0.02〜3微米的细小颗粒。本发明的颗粒制备技术可适用于食品、化妆品、生物聚合物、聚合物组合物和制药等领域。
• Sweetener compositions and uses thereof
  申请人：AJINOMOTO CO. INC

  公开号：US20040105928A1

  公开（公告）日：2004-06-03

  The present invention provides compositions containing one or more aspartyl dipeptide derivatives represented by formulas (1) and/or (2) mixed with another high intensity sweetner, such Aspartame, sugar, sugar alcohol, and oligosaccharide; food, beverages, and/or medicinal products containing these compositions, methods of using the compositions to impart sweetness in food, beverages, and/or medicinal products to impart sweetness or suppress a bitter taste; and methods of making the compositions and products.

  本发明提供了一种含有一个或多个由式(1)和/或式(2)表示的天冬氨酰二肽衍生物与另一种高强度甜味剂混合的组合物；含有这些组合物的食品、饮料和/或药品；使用这些组合物在食品、饮料和/或药品中赋予甜味或抑制苦味的方法；以及制备这些组合物和产品的方法。其中，另一种高强度甜味剂可以是阿斯巴甜、糖、糖醇和寡糖。
• Novel Blt2-Mediated Disease, Blt2 Binding Agent And the Compound
  申请人：Nakade Shinji

  公开号：US20080132574A1

  公开（公告）日：2008-06-05

  [PROBLEM] The compound that selectively binds to BLT2 and the preventive and/or therapeutic drug for BLT2-mediated disease such as skin disease are needed. [MEANS FOR SOLVING THE PROBLEMS] The present invention provides the compound with BLT2 binding activity, salt thereof, solvate thereof or prodrug thereof. Since the compound with BLT2 binding activity, particularly the compound represented by the formula (I) salt thereof, solvate thereof or prodrug thereof (symbols in formula have the same meanings as specification.) have BLT2 binding activity, it is useful for prevention and/or therapy of BLT2 mediated diseases, e.g., dermatosis, intestinal disease, HIV infection, acquired immunodeficiency syndrome, rejection to transplant, transplant rejection, graft-versus-host disease, autoimmune disease, allergic disease, inflammation, infection, ulcers, lymphoma, malignant tumor, leucaemia, arterial sclerosis, hepatitis, hepatic cirrhosis or cancer, etc.

  【问题】需要一种选择性结合于BLT2的化合物和预防和/或治疗BLT2介导的疾病，如皮肤病的药物。 【解决方法】本发明提供具有BLT2结合活性的化合物，其盐，溶剂化物或前药。由于具有BLT2结合活性的化合物，特别是由式（I）表示的化合物，其盐，溶剂化物或前药（式中的符号与说明书具有相同的含义）具有BLT2结合活性，因此对于预防和/或治疗BLT2介导的疾病，例如皮肤病，肠道疾病，HIV感染，获得性免疫缺陷综合症，移植排斥，移植物排斥，移植物抗宿主病，自身免疫性疾病，过敏性疾病，炎症，感染，溃疡，淋巴瘤，恶性肿瘤，白血病，动脉硬化，肝炎，肝硬化或癌症等具有用处。